Περίληψη:
Purpose: Circulating hormone concentrations are associated with breast cancer risk, with well-established associations for postmenopausal women. Biomarkers may represent minimally invasive measures to improve risk prediction models. Experimental Design: We evaluated improvements in discrimination gained by adding serum biomarker concentrations to risk estimates derived from risk prediction models developed by Gail and colleagues and Pfeiffer and colleagues using a nested case–control study within the EPIC cohort, including 1,217 breast cancer cases and 1,976 matched controls. Participants were pre- or postmenopausal at blood collection. Circulating sex steroids, prolactin, insulin-like growth factor (IGF) I, IGF-binding protein 3, and sex hormone–binding globulin (SHBG) were evaluated using backward elimination separately in women pre- and postmenopausal at blood collection. Improvement in discrimination was evaluated as the change in concordance statistic (C-statistic) from a modified Gail or Pfeiffer risk score alone versus models, including the biomarkers and risk score. Internal validation with bootstrapping (1,000-fold) was used to adjust for overfitting. Results: Among women postmenopausal at blood collection, estradiol, testosterone, and SHBG were selected into the prediction models. For breast cancer overall, model discrimination after including biomarkers was 5.3 percentage points higher than the modified Gail model alone, and 3.4 percentage points higher than the Pfeiffer model alone, after accounting for overfitting. Discrimination was more markedly improved for estrogen receptor–positive disease (percentage point change in C-statistic: 7.2, Gail; 4.8, Pfeiffer). We observed no improvement in discrimination among women premenopausal at blood collection. Conclusions: Integration of hormone measurements in clinical risk prediction models may represent a strategy to improve breast cancer risk stratification. ©2017 AACR.
Συγγραφείς:
Hüsing, A.
Fortner, R.T.
Kühn, T.
Overvad, K.
Tjønneland, A.
Olsen, A.
Boutron-Ruault, M.-C.
Severi, G.
Fournier, A.
Boeing, H.
Trichopoulou, A.
Benetou, V.
Orfanos, P.
Masala, G.
Pala, V.
Tumino, R.
Fasanelli, F.
Panico, S.
De Mesquita, H.B.B.
Peeters, P.H.
Van Gills, C.H.
Quirós, J.R.
Agudo, A.
Sánchez, M.-J.
Chirlaque, M.-D.
Barricarte, A.
Amiano, P.
Khaw, K.-T.
Travis, R.C.
Dossus, L.
Li, K.
Ferrari, P.
Merritt, M.A.
Tzoulaki, I.
Riboli, E.
Kaaks, R.
Λέξεις-κλειδιά:
androstenedione; biological marker; estradiol; estrone; prasterone sulfate; progesterone; prolactin; sex hormone binding globulin; somatomedin binding protein 3; somatomedin C receptor; testosterone; estradiol; prolactin; sex hormone; sex hormone binding globulin; somatomedin binding protein 3; somatomedin C; testosterone; tumor marker, adult; aged; Article; blood sampling; breast cancer; cancer risk; case control study; controlled study; disease association; estrogen receptor positive breast cancer; female; hormone blood level; human; major clinical study; postmenopause; premenopause; priority journal; blood; breast tumor; classification; genetics; metabolism; middle aged; pathology; prognosis; risk factor, Aged; Biomarkers, Tumor; Breast Neoplasms; Case-Control Studies; Estradiol; Female; Gonadal Steroid Hormones; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Middle Aged; Postmenopause; Premenopause; Prognosis; Prolactin; Risk Factors; Sex Hormone-Binding Globulin; Testosterone
